DRUG ZOMETA IN ADDITION TO THE CHEMOTHERAPY SIGNIFICANTLY INCREASES OVERALL SURVIVAL IN PREVIOUSLY UNTREATED PATIENTS WITH MULTIPLE MYELOMA
- Authors: Zhukov NV1, Zhukov N.V.1
-
Affiliations:
- Issue: No 17 (2010)
- Pages: 78-80
- Section: Articles
- URL: https://journals.eco-vector.com/2073-4034/article/view/278675
- ID: 278675
Cite item
Full Text
Abstract
Bisphosphonates have long been used successfully for the prevention of complications associated with tumors of skeletal system. Currently, however, there are increasing evidences that at least one of them - zoledronic acid - has direct antitumor activity and the ability to increase patients' survival. The Congress of the American Society of Clinical Oncology presented multicenter randomized trial Myeloma IX, confirming the ability of zoledronic acid to significantly increase overall survival of patients with multiple myeloma as compared to clodronic acid (50.0 vs 44.5 months, respectively, P = 0.0118 ). Reported at the Congress ABCSG-12 study (Austrian Breast and Colorectal Cancer Study Group-12) indicated the antitumor activity of zoledronic acid at other tumors (breast cancer).
References
- Morgan G, et al, Evaluating the Effects of Zoledronic Acid on Overall Survival in patients with multiple Myeloma: Results of the Medical Research Council Myeloma IX Study. Presented at: American Society of Clinical Oncology 2010 Annual Meeting. Abstract No. 8021.
- Gnant M, et al, Mature results from ABCSG-12: Adjuvant ovarian suppression combined with tamoxifen or anastrozole, alone or in combination with zoledronic acid, in premenopausal women with endocrine-responsive early breast cancer. Presented at: American Society of Clinical Oncology 2010 Annual Meeting. Abstract No. 533.
Supplementary files
